314 disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521–533 Glabe CC (2005) Amyloid accumulation and pathogensis of Alzhei- mer’s disease: signiﬁcance of monomeric, oligomeric and ﬁbrillar Abeta. Subcell Biochem 38:167–177 Goldstein L, Ashford JW, Busciglio J, Crutcher K, Gouras G, Kinoshita J, Mandelkow E, Sudol M (2003) Live discussion. From here to there: AbetaPP as an axonal transport receptor–how could this explain neurodegeneration in AD. 15 July 2002. J Alzheimers Dis 5:483–489 Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378–384 Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M et al (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 40:1–8 Hardy J, Gwinn-Hardy K (1998) Genetic classiﬁcation of primary neurodegenerative disease. Science 282:1075–1079 Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K (1997) Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides. Nat Med 3:1016–1020 Hashimoto M, Masliah E (1999) Alpha-synuclein in Lewy body disease and Alzheimer’s disease. Brain Pathol 9:707–720 Hashimoto M, Yoshimoto M, Sisk A, Hsu LJ, Sundsmo M, Kittel A, Saitoh T, Miller A, Masliah E (1997) NACP, a synaptic protein involved in Alzheimer’s disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun 237:611–616 Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E (1999) Oxidative stress induces amyloid-like aggre- gate formation of NACP/alpha-synuclein in vitro. Neuro Report 10:717–721 Hashimoto M, Takenouchi T, Mallory M, Masliah E, Takeda A (2000) The role of NAC in amyloidogenesis in Alzheimer’s disease. Am J Pathol 156:734–736 Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E (2001) b-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32:213–223 Hashimoto M, Rockenstein E, Masliah E (2003a) Transgenic models of alpha-synuclein pathology: past, present, and future. Ann N Y Acad Sci 991:171–188 Hashimoto M, Rockenstein E, Crews L, Masliah E (2003b) Role of protein aggregation in mitochondrial dysfunction and neurode- generation in Alzheimer’s and Parkinson’s diseases. Neuromo- lecular Med 4:21–36 Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2004) State-speciﬁc projections through 2025 of Alzheimer disease prevalence. Neurology 62:1645 Hof PR, Morrison JH (1991) Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differen- tial vulnerability in Alzheimer’s disease. Exp Neurol 111:293– 301 Hof P, Morrison J (1994) The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. In: Terry R, Katzman R, Bick K (eds) Alzheimer disease. Raven Press, New York, pp 197–230 Holcomb L, Gordon M, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders P, Zehr C, O’Campo K, Hardy J, Prada C-M, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97–100 Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deﬁcits, Ab 123 Neurotox Res (2009) 16:306–317 elevation, and amyloid plaques in transgenic mice. Science 274:99–102 Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56:1095–1097 Ihara M, Yamasaki N, Hagiwara A, Tanigaki A, Kitano A, Hikawa R, Tomimoto H, Noda M, Takanashi M, Mori H, Hattori N, Miyakawa T, Kinoshita M (2007) Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 53:519– 533 Iwai A (2000) Properties of NACP/alpha-synuclein and its role in Alzheimer’s disease. Biochim Biophys Acta 1502:95–109 Iwai A, Yoshimoto M, Masliah E, Saitoh T (1995a) Non-A beta component of Alzheimer’s disease amyloid (NAC) is amyloi- dogenic. Biochemistry 34:10139–10145 Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (1995b) The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467–475 Iwai A, Masliah E, Sundsmo MP, DeTeresa R, Mallory M, Salmon DP, Saitoh T (1996) The synaptic protein NACP is abnormally expressed during the progression of Alzheimer’s disease. Brain Res 720:230–234 Jao CC, Der-Sarkissian A, Chen J, Langen R (2004) Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc Natl Acad Sci USA 101:8331–8336 Jellinger KA, Attems J (2006) Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol (Berl) 112:253–260 Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Waka- bayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159:2215–2225 Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37:925–937 Kazlauskaite J, Pinheiro TJ (2005) Aggregation and ﬁbrillization of prions in lipid membranes. Biochem Soc Symp 72:211–222 Kim SI, Yi JS, Ko YG (2006) Amyloid beta oligomerization is induced by brain lipid rafts. J Cell Biochem 99:878–889 Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Bjorklund A (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha- synuclein in the nigrostriatal system. J Neurosci 22:2780–2791 Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 24:219–224 Klein RL, King MA, Hamby ME, Meyer EM (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 13:605–612 Koo EH, Squazzo SL (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 269:17386–17389 Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, Edwards RH, Fortin DL (2005) A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem 280:31664–31672 Kurata T, Kawarabayashi T, Murakami T, Miyazaki K, Morimoto N, Ohta Y, Takehisa Y, Nagai M, Ikeda M, Matsubara E, Westaway D, Hyslop PS, Harigaya Y, Kamiya T, Shoji M, Abe K (2007) Enhanced accumulation of phosphorylated